Global Ophthalmology Therapeutics Market – Gene Therapies and First-in-Class Targets Offer Novel Treatments for Substantial Unmet Needs in a Pipeline Dominated by Angiogenic and Immune Signaling Drugs – Research and Markets

DUBLIN–(BUSINESS WIRE)–The “Frontier
Pharma: Ophthalmology Therapeutics – Gene Therapies and First-in-Class
Targets Offer Novel Treatments for Substantial Unmet Needs in a Pipeline
Dominated by Angiogenic and Immune Signaling Drugs”
drug
pipelines has been added to Research and Markets’
offering.

The report Frontier Pharma: Ophthalmology Therapeutics Gene
Therapies and First-in-Class Targets Offer Novel Treatments for
Substantial Unmet Needs in a Pipeline Dominated by Angiogenic and Immune
Signaling Drugs
assesses first-in-class innovation in the
ophthalmology pipeline, highlighting key trends in the distribution of
these products. In-depth analysis reveals that the level of innovation
within the therapy area pipeline is high, with strong potential for
drugs to address unmet needs and be commercially lucrative.

Ophthalmology pipeline has a highly active deals landscape. There were
271 licensing deals and 152 co-development deals completed between 2006
and 2016 across the therapy area, of which 94 licensing deals and 33
co-development deals had a disclosed value. Many products in the
ophthalmology pipeline have previously been involved in licensing and
co-development deals. Most of these are in the Preclinical stage of
development, although many deals also took place for products at Phase
II.

The pipeline contains a diverse range of molecular targets, and no
single target dominates by any clear margin. However, products acting on
components of the immune system largely cytokines and cytokine receptors
and its regulatory signaling pathways make up the largest segment,
followed by angiogenesis inhibitors. Generally, the composition by
molecular target across the pipeline suggests that product development
is shifting away from the type of therapies that currently dominate the
market, indicating that the available therapeutic options could
diversify.

Key Topics Covered:

1. List of Tables & Figures

2 Executive Summary

3 The Case for Innovation

4 Clinical and Commercial Landscape

5 Assessment of Pipeline Product Innovation

6 Signaling Network, Disease Causation and Innovation Alignment

7 First-in-Class Target Evaluation

8 Deals and Strategic Consolidations

9 Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/ld3zvz/frontier_pharma

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Pharmaceuticals,
Genomics